Chiron Corp. and Cetus Corp. said Monday that the DelawareChancery Court has formally denied a motion brought byEastman Kodak Co. seeking to enjoin the sale of Cetus'polymerase chain reaction technology to Hoffmann-La RocheInc. The order confirms Roche's agreement, filed Dec. 5, to bebound by the decision of an arbitration pending between Cetusand Kodak over rights to the technology. Cetus shares(NASDAQ:CTUS) closed unchanged at $19. Chiron(NASDAQ:CHIR) rose 25 cents to $64.

(c) 1997 American Health Consultants. All rights reserved.